Features of HLA‐A*02 in Identifying Eligible Patients for Tecelra TCR‐T Therapy
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Science"
DOI: 10.1111/cas.70048
Abstract: This study investigates the molecular mechanisms behind HLA‐A*02 subtypes' differential responses to Tecelra, a TCR‐engineered T‐cell therapy targeting MAGE‐A4. Using computational tools, the study identifies specific HLA‐A*02 alleles, such as HLA‐A*02:07, HLA‐A*02:05, and others, with… read more here.
Keywords: identifying eligible; hla identifying; therapy; eligible patients ... See more keywords